The effect of a new direct Factor Xa inhibitor on human osteoblasts: An in-vitro study comparing the effect of rivaroxaban with enoxaparin

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Solayar, Gandhi N ^a   Walsh, Pauline M ^a   Mulhall, Kevin J ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; ENOXAPARIN; MESSENGER RNA; OSTEOCALCIN; RIVAROXABAN; TRANSCRIPTION FACTOR RUNX2; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BMP2 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; RUNX2 PROTEIN, HUMAN; THIOPHENE DERIVATIVE;

ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; REAL TIME POLYMERASE CHAIN REACTION; AGED; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM;

AGED; ALKALINE PHOSPHATASE; ANTICOAGULANTS; BONE MORPHOGENETIC PROTEIN 2; CELL SURVIVAL; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ENOXAPARIN; FACTOR XA; FEMALE; GENE EXPRESSION; HUMANS; MORPHOLINES; OSTEOBLASTS; OSTEOCALCIN; RNA, MESSENGER; THIOPHENES;

EID: 80055023998     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-247     Document Type: Article

References (34)

1. Rationale for thromboprophylaxis in lower joint arthroplasty. Colwell CW Jr, American journal of orthopedics (Belle Mead, NJ 2007 36 9 Suppl 11 13
2. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Turpie AG, American journal of surgery 1991 161 4 532 536 10.1016/0002-9610(91)91126-4 1852136
3. The effects of heparin and low molecular weight heparins on bone. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG, Thromb Res 2008 122 3 293 298 10.1016/j.thromres.2006.10.025 17716711 (Pubitemid 351888881)
4. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Wawrzynska L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A, Pathophysiol Haemost Thromb 2003 33 2 64 67 10.1159/000073848 14624046 (Pubitemid 37449280)
5. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Walenga JM, Bick RL, Med Clin North Am 1998 82 3 635 658 10.1016/S0025-7125(05)70015-8 9646784 (Pubitemid 28244029)
6. Heparin-induced spinal fractures. Squires JW, Pinch LW, Jama 1979 241 22 2417 2418 10.1001/jama.241.22.2417 439319 (Pubitemid 9198268)
7. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Dahlman TC, Am J Obstet Gynecol 1993 168 4 1265 1270 8475973 (Pubitemid 23122178)
8. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P, Thromb Haemost 1996 75 2 254 257 8815571
9. European Commission approval for Xarelto. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR--Public-assessment-report/human/000944/WC500057122. pdf
10. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR, J Bone Joint Surg Br 2009 91 5 636 644 10.1302/0301-620X.91B5.21691 19407299
11. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A, J Thromb Haemost 2005 3 3 514 521 10.1111/j.1538-7836.2005.01166.x 15748242 (Pubitemid 41632877)
12. Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Kubitza D, Becka M, Mueck W, Zuehlsdorf M, Br J Clin Pharmacol 2007 63 4 469 476 10.1111/j.1365-2125.2006. 02776.x 17100983 (Pubitemid 46426627)
13. Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ, Ladner RD, Nucleic Acids Res 2009 37 1 78 95 10.1093/nar/gkn910 19015155
14. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP, AIDS Res Hum Retroviruses 2007 23 12 1521 1530 10.1089/aid.2007.0112 18160010
15. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, Baron AE, Barton PL, Am J Obstet Gynecol 1994 170 3 862 869 8141217 (Pubitemid 24224715)
16. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C, Thromb Haemost 1994 71 1 7 11 8165649 (Pubitemid 24023779)
17. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E, Thromb Res 1999 96 4 275 282 10.1016/S0049-3848(99)00110-3 10593430
18. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Matziolis G, Perka C, Disch A, Zippel H, Calcified tissue international 2003 73 4 370 379 10.1007/s00223-002- 2091-5 12874702 (Pubitemid 37409424)
19. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O, Br J Surg 2005 92 2 177 183 10.1002/bjs.4809 15584059 (Pubitemid 40269331)
20. Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts. Magnusson P, Sharp CA, Farley JR, Clin Chim Acta 2002 325 1-2 59 70 10.1016/S0009-8981(02)00248-6 12367767 (Pubitemid 35279626)
21. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG, Thrombosis and haemostasis 1998 80 3 413 417 9759620 (Pubitemid 28438735)
22. Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro. Osip SL, Butcher M, Young E, Yang L, Shaughnessy SG, Thrombosis and haemostasis 2004 92 4 803 810 15467912 (Pubitemid 39386708)
23. Osteocalcin and bone. Wada S, Fukawa T, Kamiya S, Clinical calcium 2007 17 11 1673 1677 17982186
24. Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. Prince M, Banerjee C, Javed A, Green J, Lian JB, Stein GS, Bodine PV, Komm BS, J Cell Biochem 2001 80 3 424 440 10.1002/1097-4644(20010301)80:3<424::AID- JCB160>3.0.CO;2-6 11135373 (Pubitemid 32141498)
25. Regulating bone growth and development with bone morphogenetic proteins. Leboy PS, Ann N Y Acad Sci 2006 1068 14 18 10.1196/annals.1346.003 16831901 (Pubitemid 43824132)
26. BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT, J Bone Miner Res 2006 21 4 637 646 10.1359/jbmr.060109 16598384
27. BMP2 signaling in bone development and repair. Rosen V, Cytokine & growth factor reviews 2009 20 5-6 475 480 10.1016/j.cytogfr.2009.10.018 22046560
28. BMP and osteoclastogenesis. Nakamura M, Udagawa N, Yamamoto Y, Nakamura H, Clinical calcium 2006 16 5 809 815 16679623
29. Cbfa1 isoforms exert functional differences in osteoblast differentiation. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, Komori T, Nakatsuka M, J Biol Chem 1999 274 11 6972 6978 10.1074/jbc.274.11.6972 10066751 (Pubitemid 29140505)
30. Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Sierra J, Villagra A, Paredes R, Cruzat F, Gutierrez S, Javed A, Arriagada G, Olate J, Imschenetzky M, Van Wijnen AJ, et al. Mol Cell Biol 2003 23 9 3339 3351 10.1128/MCB.23.9.3339-3351.2003 12697832 (Pubitemid 36459245)
31. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, Nishihara T, J Cell Physiol 2008 216 3 844 850 10.1002/jcp.21468 18449905
32. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG, Blood 1996 88 4 1314 1320 8695849 (Pubitemid 26276806)
33. Effects of heparin on osteoclast activity. Chowdhury MH, Hamada C, Dempster DW, J Bone Miner Res 1992 7 7 771 777 1642146
34. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y, Bone 2007 41 2 165 174 10.1016/j.bone.2007.04.190 17560185 (Pubitemid 47001824)